Achieve Life Sciences, Inc. (ACHV)
Nasdaq · Healthcare · Biotechnology
$7.01−3.18%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $723M
- 52-week range
- $2.62 – $8.64
- 52-week change
- +118.07%
- EPS (trailing)
- −$1.69
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$54.6M
- Diluted EPS
- −$1.25
- Free cash flow
- −$49.5M
From the company’s annual report on SEC EDGAR.
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Headquarters: Bothell, United States · 28 employees · achievelifesciences.com